Alpha Tau Medical Ltd. announced on September 2, 2025, that it has initiated a multi-center clinical trial in the United States.
2 reports, 1 independent
Updated Sep 2
Gone quiet
- Reports
- 2
- Developments
- 3
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Alpha Tau Medical Ltd. announced on September 2, 2025, that it has initiated a multi-center clinical trial in the United States.
How it developed
Newest first. Tap a step to see who reported it.- Alpha Tau Medical Ltd. developed the Alpha DaRT therapy for solid tumors, leveraging technology from Tel Aviv University.Sub-event
Alpha Tau Medical Ltd. announced on September 2, 2025, that it has initiated a multi-center clinical trial in the United States.1 source
FDA granted IDE approval for Alpha Tau's pilot study; Alpha Tau also secured funding from Oramed.1 source
Coverage
Newest first; wire copies grouped- GlobeNewswireAlpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial – First patient treatment marks successful initiation of multi-center pilot study in Alpha DaRT U
- GlobeNewswireAlpha Tau Announces Second Quarter 2025 Financial Results and Provides Corporate Update - FDA approval of IDE to conduct a U.S. pilot study exploring the use of Alpha DaRT in patients with recurrent